ZURICH, Dec 27 (Reuters) - Swiss drugs regulator Swissmedic said on Monday it approved Ronapreve, an antibody treatment jointly developed by Roche and Regeneron (REGN.O) , to treat COVID-19 patients.
"In this procedure, no data on efficacy against the Omicron variant were submitted," Swissmedic said in a statement.
The antibody treatment was already authorised for prescription in Switzerland under COVID-19 Ordinance 3 since April 15, Swissmedic said.
Register now for FREE unlimited access to Reuters.com
Reporting by Silke Koltrowitz, Editing by Miranda Murray
Our Standards: The Thomson Reuters Trust Principles.